Physician profile
Naheed T Bashir
NPI 1245355916
$4,089.24
in general payments reported to CMS, 2019-2025
27 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $552 · 2021: $849 · 2022: $470 · 2023: $595 · 2024: $513 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,767.96 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $533.54 | 2019-2025 | Xtampza, Belbuca |
| Biodelivery Sciences International, INC. | $239.69 | 2019-2021 | |
| Valinor Pharma, LLC | $218.19 | 2023-2025 | Movantik |
| Abbott Laboratories | $202.39 | 2019-2025 | Proclaim, Eterna |
| Abbvie INC. | $160.28 | 2021-2025 | |
| Redhill Biopharma INC. | $99.25 | 2021 | |
| Pfizer INC. | $97.48 | 2019-2024 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $74.37 | 2022 | |
| Hikma Pharmaceuticals USA | $70.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $66.46 | 2020-2021 | |
| Daiichi Sankyo INC. | $66.33 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $61.95 | 2024-2025 | |
| Lilly USA, LLC | $60.73 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.26 | 2019-2020 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.94 | 2021 | |
| Kaleo, INC. | $21.79 | 2019 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Virtus Pharmaceuticals LLC | $17.86 | 2021 | |
| Sentynl Therapeutics, INC. | $16.65 | 2019 | |
| Depuy Synthes Sales INC. | $16.55 | 2020 | |
| Fidia Pharma USA INC. | $16.21 | 2025 | Hymovis |
| Si-Bone, INC. | $14.37 | 2023 | |
| Shionogi INC | $13.09 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naheed Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.